Objectives: A future treatment for uncomplicated malaria will contain at least one component that exerts a rapid rate of kill. We describe here the validation and application of a simple, robust and rapid bioluminescencebased assay for the determination of the initial rate of kill in intra-erythrocytic asexual stages of Plasmodium falciparum.
Introduction
The past decade has seen, for the first time in generations, a decline in mortality and morbidity from malaria, largely on account of the use of effective antimalarials and the widespread coverage of insecticide-treated bed nets and other transmission-preventative measures. 1 However, the estimated number of deaths is still very high, estimated at 438000 in 2015, 2 the majority of which are among African children under 5 years of age. In the same period, the malaria parasite has assembled more countermeasures than ever before to overcome chemotherapy, with some parts of the world reporting clinical failures to artemisinin and artemisinin combination therapy, the last effective antimalarial drug class currently available. [3] [4] [5] [6] [7] The need to develop new drugs with novel modes of action, which circumvent current parasite resistance mechanisms, therefore remains an urgent priority. 8, 9 Towards this aim, in the past 5 years Medicines for Malaria Venture (MMV) has coordinated the screening of >5 million compounds against Plasmodium falciparum in vitro. This has generated nearly 30 000 compounds inhibiting in the submicromolar range. [10] [11] [12] However, there is currently no clear and informed path to rationally triage the 20000-30000 hits that are now at our disposal. At best, the pharmaceutical and academic malaria research communities will be able to progress 20-30 chemotypes down the traditional discovery and development pathway within the next decade. Technology platforms able to identify the most effective and tractable chemotypes for progression into the drug development pipeline are therefore urgently needed. Key features of the sought-after next-generation antimalarial for the treatment of uncomplicated malaria, termed single-exposure radical cure and prophylaxis (SERCaP), have been rationalized and have resulted in the recommendation of a series of target candidate profiles (TCPs) for the component parts of this drug combination therapy. TCP1 emphasizes the requirement for a component part of SERCaP to rapidly eliminate the initial parasite burden, ideally as fast as artesunate, but with a minimal essential requirement to do so as fast as chloroquine. 9 V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com A current bottleneck in antimalarial discovery projects is that the current gold standard in the determination of killing dynamics for new inhibitors is slow, necessitating between 3 and 4 weeks of recrudescence parasite growth following drug exposure. 13 To address this bottleneck, we describe here the validation of a microplate-based bioluminescence assay that provides, within 6 h, a determination of a compound's initial cytocidal action. Benchmarking these data against existing antimalarial compounds, for which rate-of-kill pharmacodynamics are known, provides a relative rate of initial kill and thus a means to triage a compound's activity against the minimal essential and ideal criteria as TCP1 candidates. The utility of this rapid, simple and robust assay format is demonstrated in a relative rate of kill screen of the MMV Malaria Box, an open-access resource provided for drug discovery in malaria and neglected tropical diseases. 14 The MMV Malaria Box contains 400 compounds distilled from the initial large chemical screens performed by St Jude Children's Research Hospital, Novartis and GlaxoSmithKline. [10] [11] [12] These compounds reflect a cross-section of the chemical diversity available in the 20000-30000 hits, providing 200 starting points for oral drug discovery (termed drug-like) and 200 compounds to explore malaria parasite biology (termed probe-like). Our findings suggest this bioluminescence relative rate of kill (BRRoK) assay provides the required throughput and discrimination necessary to assist in the decision-making process to prioritize leads in the 20000-30000 antimalarial compound set for further development.
Materials and methods

Drug stocks
Antimalarial drugs were sourced from Sigma-Aldrich and prepared as follows: atovaquone (10 mM in DMSO), artemether (50 mM in ethanol), chloroquine (100 mM in deionized water), dihydroartemisinin (50 mM in methanol), mefloquine (50 mM in DMSO), piperaquine (100 mM in ethanol), pyronaradine (100 mM in deionized water), quinine (100 mM in ethanol) and tafenoquine (100 mM in DMSO). The prepared drugs were stored at À20 C. The Malaria Box was provided by MMV (www.mmv.org) and was provided as 20 lL solutions of 10 mM concentration in DMSO and stored at À20 C. In all experiments, the final maximum final concentration of solvent was 0.6% (v/v).
P. falciparum cell culture
The transgenic Dd2 P. falciparum clone (Dd2 luc ) expresses luciferase under the control of Pfpcna flanking sequences to produce a strong peak of temporal reporter expression during S-phase in trophozoite-stage parasites. 15, 16 Dd2 luc parasites were cultured using standard continuous culture conditions [RPMI 1640 medium supplemented with 37.5 mM HEPES, 10 mM D-glucose, 2 mM L-glutamine, 100 lM hypoxanthine, 25 lg/mL gentamicin, 4% (v/v) human serum, 0.25% (v/v) Albumax II, 5 nM WR99210 and 2.5 lg/mL blasticidin S] at a 2% haematocrit in an atmosphere of 1% O 2 , 3% CO 2 and 96% N 2 . WR99210 and blasticidin S drug selection media were removed 48 h prior to initiation of fluorescence and bioluminescence assays. Staging and parasitaemia of the in vitro culture were assessed by light microscopy of Giemsa-stained thin blood smears. Synchronization of cultures was attained using sequential sorbitol lysis treatment, 17 with experiments carried out at least one intra-erythrocytic cycle later.
Concentration-response assays using bioluminescent and fluorescent assay formats
Trophozoite-stage (20-26 h post-infection) cultures of Dd2 luc (100 lL, 2% parasitaemia, 4% haematocrit, n ¼ 3) were added to 96-multiwell plates containing 100 lL of pre-dosed (a final 5-fold dilution series) complete culture medium. On each assay plate, three wells containing 200 lL of 2% parasitaemia cell culture (2% haematocrit) in the absence of drugs served as a positive control (100%), whereas the same culture mix in the presence of a 10 lM concentration of chloroquine served as a negative growth control (0%). The outermost wells on each plate contained 200 lL of incomplete medium (complete culture medium without human serum or Albumax II supplements) to minimize edge effects from evaporation during incubation.
To estimate the IC 48h 50 , the parasite inoculum was incubated continuously in the presence of the compound/drug for 48 h prior to assay. Estimation of the LC 6h 50 was carried out using a modification of the protocol originally described by Paguio et al. 18 Here, the parasite inoculum was incubated for 6 h in the presence of compound/drug. The infected erythrocyte cultures were collected by centrifugation (3000 g, 5 min at room temperature) and the medium supernatant was discarded. Three repeat washes with 10 volumes of complete cell culture medium and centrifugation were completed before re-suspending the infected erythrocytes in 200 lL of 37 C complete culture medium for an additional 42 h in the absence of compound/drug prior to assay. Luciferase and malaria SYBR green I fluorescence (MSF) assays were also carried out immediately following the 6 h incubation in drug/compound; these data were used to estimate the EC 6h 50 . Experiments were carried out as technical triplicates on the same plate, with three independent biological repeats of each plate performed.
For bioluminescence assays, relative light units were measured using the luciferase assay system (Promega, UK). A standard single-step lysis procedure was used throughout. 19 Samples (40 lL) of P. falciparum culture were transferred to a white 96-multiwell plate (Greiner, UK), 10 lL of passive lysis buffer (Promega, UK) was added and the sample was homogenized by pipetting. An equal volume, 50 lL, of the supplied luminogenic substrate was mixed with the lysed parasites and the bioluminescence was measured for 2 s in a Glomax-Multi Detection System (Promega, UK).
Fluorescent signals were measured using a standard MSF assay 20 as modified. 16 MSF lysis buffer [100 lL of 20 mM Tris (pH 7.5), 5 mM EDTA, 0.008% (w/v) saponin and 0.08% (v/v) Triton X-100] containing SYBR Green I (1 Â final concentration, from 5000Â stock supplied by Invitrogen, UK) was added to 100 lL of Dd2 luc aliquoted onto a black 96-multiwell plate (Greiner, UK). Well contents were homogenized by pipetting and incubated for 1 h in the dark at room temperature. The fluorescent signal was measured using the blue fluorescence module (excitation 490 nm, emission 510-570 nm) in a Glomax-Multi Detection System (Promega, UK).
Irrespective of the assay, growth was expressed as a proportion of the untreated control (i.e. 100%) and calculated as follows: 100
, where l (S) , l (þ) and l (À) represent the means for the sample in question and 100% and 0% controls, respectively. Note that, as a complete kill could not be technically demonstrated to be achieved within 6 h, the 0% control for the LC 6h 50 and EC 6h 50 determination was established as a 48 h continual exposure to 10 lM chloroquine. The percentage growth was plotted against log 10 -transformed drug concentration and the parameters described above were determined using a non-linear regression (sigmoidal concentration-response/variable slope equation) in GraphPad Prism v5.0 (GraphPad Software, Inc., San Diego, CA, USA).
BRRoK assay
Trophozoite-stage (20-26 h post-infection) cultures of Dd2 luc (100 lL, 2% parasitaemia, 4% haematocrit, n ¼ 3) were added to 96-multiwell plates containing 100 lL of pre-dosed (final 3-fold IC 50 dilution series) complete culture medium and mixed by pipetting. The multiwell plate was incubated for 6 h at 37 C. Samples (40 lL) from each well were removed and the bioluminescent signal was measured using the luciferase single-step lysis protocol described above. Controls in each biological replicate consisted of trophozoite-stage culture with no drug added (100%) or uninfected erythrocytes (0%). The mean and SD of bioluminescence data from three Ullah et al.
independent biological repeats were expressed as a proportion of the untreated control (100%) using the calculation shown above. For the screening of the MMV Malaria Box (6 h assays using a 9 Â IC 50 to 0.3 Â IC 50 series), a principle components analysis was performed on the bioluminescence endpoints (expressed as a percentage of untreated control) using the KNIME analytics platform to reduce the dimensionality of these data sets. 21 As the first principle component (PC1) captured 89% of the variance in the data, a zero-meaned PC1 value was used to represent the BRRoK parameter. The Z 0 score of the BRRoK assay was calculated as follows:
, where l (þ) and r (þ) are the mean and SD of the no-drug (untreated) positive control, respectively, and l (À) and r (À) are the mean and SD from uninfected erythrocytes (negative control), respectively. 22 The signal/background (S/B) ratio was calculated as follows:
Results
A microplate-based bioluminescence assay monitors a concentration-and time-dependent loss of parasite viability immediately following drug perturbation P. falciparum genetically modified to express a luciferase reporter gene (Dd2 luc ) shows a time-and concentration-dependent loss of bioluminescence signal immediately, i.e. within 6 h, following exposure to the rapid-acting cytocidal drugs chloroquine, dihydroartemisinin and artemether. 16 By contrast, exposure to the cytostatic drug atovaquone results in no apparent loss in bioluminescence signal over the same time frame. 16 To validate that this drug-induced loss of bioluminescence reports a loss in parasite viability, Dd2 luc parasites were subjected to a lethality assay adapted from that originally described by Paguio et al. 18 Early trophozoitestage parasites were exposed to a serial dilution of antimalarial drug in a 6 h bolus, and the drug was then washed off before replacing the parasites in culture for 42 h to complete a cycle of intra-erythrocytic development. The principle here is that parasites killed during the drug bolus will not divide after removal of the drug, whereas those inhibited by the drug will recommence growth upon removal of drug pressure. A range of antimalarial drug classes were tested to explore the applicability of this approach, including the 4-aminoquinoline chloroquine, the 8-aminoquinoline tafenoquine, the 4-methanolquinolines mefloquine and quinine, the bisquinoline piperaquine, the sesquiterpene lactones dihydroartemisinin and artemether, and a naphthoquinone, atovaquone.
Three log concentration-response curves, normalized against untreated controls, were fitted using data derived from either a bioluminescence assay (luciferase) or an MSF assay of DNA content [see Figure S1 (available as Supplementary data at JAC Online) for an experimental schema]. These curves ( Figure 1 and Figure S2 ) report the following parameters (Table 1) : a 50% effective concentration recorded immediately following the drug bolus but prior to drug wash-out (EC 6h 50 ); a 50% lethal concentration estimate following drug wash-out and re-culture (LC 6h 50 ); and a 50% inhibitory concentration estimate following 48 h of continuous culture in the presence of the drug (IC 48h 50 ). The majority of drugs show a right shift in the lethal concentration curve compared with that of the inhibitory concentration, reflecting the higher concentration of drug required to effect a kill within a 6 h window of exposure ( Figure 1 and Figure S2 ). As expected, the right shift was more pronounced for the quinolone drugs than for the artemisinins. 18, 23 The minor shift in lethal concentration for dihydroartemisinin and artemether likely reflects their formation of covalent adducts with their target(s), rendering them resistant to the wash steps, the use of trophozoite-stage parasites in this assay as well as their profoundly rapid in vitro rate of kill. 13, 23, 24 As previously shown, IC 48h 50 data developed using either MSF or bioluminescence assays are essentially identical. 16 The same observation for the LC 6h 50 assay data, whilst not unexpected, 50 (see the main text for definitions) were determined using each assay format (reported in Table 1 ). Data represent the means of three biological replicates, with SD indicated by error bars. See Figure S1 for the same charts for artemether, quinine, piperaquine and tafenoquine. Note that non-linear regression for EC 6h 50 estimates using the MSF assay were not possible. ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; MQ, mefloquine.
Relative rate of kill for antimalarials JAC is shown here for the first time, to our knowledge. Clear differences between the MSF and bioluminescence assays immediately following the 6 h drug bolus (EC 6h 50 ) are, however, evident. Here, the intrinsic instability of the luciferase reporter protein (t1 =2 of $1.5 h) 16 compared with that of the far more stable DNA biomarker (reported in the MSF assay) offers an apparently more dynamic report of immediate drug action during this 6 h period. Importantly, the EC 6h 50 values determined using the bioluminescence assay (without drug wash and reculture) are almost identical to the LC 6h 50 estimated using either assay format. The observation that the 6 h bioluminescence curve closely fits that of the lethal concentration curve for the majority of drugs indicates that the loss of bioluminescence not only apparently reports loss of viability, but also that this 6 h assay provides a rapid determination of the immediate cytocidal action of these drugs. The sole exception, atovaquone, shows no reduction in the bioluminescence signal within 6 h, a reflection of its previously reported pharmacodynamic killing lag time. 13 To compare the relative concentration-dependent effects of different antimalarial drugs, a revised bioluminescence assay was devised that utilized fold changes in IC 50 concentrations to ensure exposure to equipotent concentrations of drug. Here, Dd2 luc parasites were exposed to a 3-fold serial dilution (81-0.33 Â IC 50 ) for 6 h, with the bioluminescent signal, normalized to an untreated control at the same timepoint, plotted against drug concentration ( Figure 2 ). These data illustrate an apparent saturation in the immediate lethal effect of drug concentrations >9 Â IC 50 for all, except atovaquone, of the drugs tested. This observation is in agreement with the findings of Sanz et al., 13 who suggest that at a 10 Â IC 50 concentration the maximal rate of in vitro kill was achieved. Direct comparison between the data shown in Figure 2 indicates an apparent relative ranking order of (artemisinin > chloroquine > 4-methanolquinolines > atovaquone) that is identical to the relative order of rate of kill described both in vivo and in vitro for the same drugs. [25] [26] [27] [28] [29] To explore this correlation further, linear regression analysis was performed between the normalized bioluminescent signals produced for each drug concentration tested and the in vitro parasite reduction ratio (PRR; a log ratio between parasitaemia at the onset of treatment and that after 48 h of exposure) and parasite clearance time (PCT; time of drug exposure to elicit a 99.9% reduction in parasitaemia) reported in Sanz et al. 13 ( Figure 3 and Figures S3 and S4 ). Comparison of bioluminescence against the PCT shows a strong, and significant, correlation at higher concentrations of drug, with the slope and intercept of the regression analysis essentially unchanged at concentrations >9 Â IC 50 , reflecting an apparent saturation in the rate of kill achieved at these concentrations (Figure 3c and Figure  S3 ). Comparisons with the log PRR show a strengthening trend with higher concentrations of drug ( Figure S4 ), although these just fail to reach a level of significance (a ¼ 0.05). Here, the available shared data (artemisinins are excluded as log PRR is only reported as >8) and the limited distribution in log PRR for the quinoline drugs used would appear to be the likely limitations in achieving a significant correlation. Ullah et al.
Screening the Malaria Box for compounds that exert a rapid cytocidal effect
The application of a microplate-based bioluminescence assay to quickly identify compounds that exert an immediate cytocidal effect was explored using the compound set available in the MMV Malaria Box. Using a 48 h MSF assay, IC 50 data were developed here in the Dd2 luc clone for 396 compounds, the remaining 4 being omitted as insufficient material was available. These data have been deposited in the ChEMBL -Neglected Tropical Disease Open Access repository (ChEMBL3392923). Of these 396 compounds, sufficient material was available for 372 to complete a 6 h bioluminescence cidality assay using a serial 3-fold dilution of compounds between 9 Â IC 50 and 0.33 Â IC 50 ; this range was selected to monitor the range of initial cytocidal action without the saturation effects observed at higher concentrations ( Figure 3) . We term this the BRRoK assay, as the initial cytocidal activity of each compound is compared against a set of benchmark antimalarials for which in vitro rates of action are known. Log concentration-normalized bioluminescence signal plots for all 372 compounds are reported in Figures S5 and S6 . See also Table S1 for compound positions in these figures. Ten assay plates (each with n ¼ 3 replicates) of Dd2 luc exposed for 6 h to either no drug (100% growth) or uninfected erythrocytes (0%) allow the Z 0 score, S/B ratio and coefficient of variation (CV) assay parameters to be determined. The 95% CIs for Z 0 score (0.9-0.97), maximum CV (0.96%-2.98%) and S/B ratio (806-993) indicate a robust and sensitive microplate-based assay format. 22 Using the mean and SD of the normalized bioluminescence signal for each IC 50 -fold concentration in the BRRoK assay, a principle components analysis was carried out to capture the concentration-dependent effects in a single parameter ( Figure S7 and Tables S2 and S3 ) derived when correlating in vitro PCT and log PRR data against the loss of bioluminescence signal at the higher fold-IC 50 drug concentrations tested. ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; MQ, mefloquine; PPQ, piperaquine; PYN, pyronaridine.
Relative rate of kill for antimalarials JAC a sequential order of the initial cytocidal effect exerted by the 372 MMV compounds screened (Table S4) , with lower values of PC1 representing a greater cytocidal effect. This order of initial cytocidal effect is then informed by comparison against the initial cytocidal effect provided for each of the benchmark antimalarial compounds, providing the necessary surrogate information regarding the initial relative rate of kill for the MMV compounds. Consequently, the BRRoK assay indicates that 53 MMV compounds exert an initial rate of kill at least the same as that for chloroquine (PC1 ¼ À73.7), with 17 ( Figure S8 ) of these compounds showing an initial rate of kill at least as good as that of dihydroartemisinin (PC1 ¼ À97.4). Support for the surrogacy of PC1 in informing a compound's initial rate of kill is provided by comparing PC1 with the in vitro estimates of log PRR and PCT for the benchmark antimalarial drugs tested (Figure 4) . 13 This comparison shows significant correlations between both PCT (r 2 ¼ 0.91, P ¼ 0.003) and log PRR (r 2 ¼ 0.78, P ¼ 0.05) with the PC1 values determined in the BRRoK assay.
Plotting PC1 against the IC 50 for the MMV compounds screened provides a simple means to explore the interplay between the IC 50 potency and relative initial rate of kill against a background of known antimalarial drug benchmarks ( Figure 5 ). Potent, low-IC 50 compounds with an initial rapid rate of kill, exemplified by artemisinins (i.e. dihydroartemisinin), occupy the bottom-left quadrant of this plot. Atovaquone, whilst potent in terms of its IC 50 , is a slowacting drug and occupies the upper left-hand quadrant. This analysis reveals that the 372 Malaria Box compounds tested display a wide range of apparent initial rates of kill, but also that, as would be expected from previous in vitro assays of rate of kill, that there is no correlation between IC 50 and rate of kill (r 2 ¼ 0.1). 13, 30 Also, as would be expected from the MMV Malaria Box, where compounds have been selected as starting points for drug discovery programmes rather than IC 50 potency, no compound tested falls within the optimal lower-left quadrant of this plot.
Discussion
The development of the next generation of medicines for the treatment of uncomplicated malaria recognizes the need for a combination of small-molecule drugs that meets a series of challenging targets around efficacy, cost and safety. 8, 9, 31 Amongst these targets is the requirement to quickly clear the parasite burden through the action of (at least one) rapidly acting cytocidal drug within this combination therapy. 9 Here, we describe the development of a rapid and robust assay for the screening of fast-acting cytocidal compounds against the intra-erythrocytic trophozoite stages of P. falciparum. Moreover, the microplate-based format and minimal experimental manipulations required to complete the assay offers the potential for it to be readily scaled for high-throughput screening of compound libraries such as the Tres Cantos Antimalarial Set (TCAMS) to triage hits with this rapid killing kinetic. Table  S4 for PC1 and IC 50 data for individual compounds. The minimum essential threshold (broken horizontal line) and ideal threshold (continuous horizontal line) for TCP1 candidates are indicated based on the BRRoK assay data for chloroquine and dihydroartemisinin, respectively. ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; MQ, mefloquine; PPQ, piperaquine; PYN, pyronaridine; QN, quinine. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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The utility of this assay was demonstrated through a medium-throughput screen of 372 compounds sourced from the Malaria Box, an open-access resource provided by the MMV to pump-prime antimalarial drug development.
14 Here, the concentration-dependent loss of bioluminescence signal for these compounds was compared against those for a range of benchmark antimalarial drugs, providing a simple relative assessment of the initial rate of kill for each MMV compound. Thus, 53 compounds in the MMV Malaria Box were shown to have an initial rate of kill at least as good as chloroquine, with 17 of these compounds showing an initial rate of kill better than that for dihydroartemisinin. This relative description of the initial rate of kill relates directly to the minimum essential and ideal criteria specified for a TCP1 component of a future SERCaP drug by MMV. 9 Thus, whilst the BRRoK assay does not provide a direct measurement of the rate of kill in terms of the currently defined PRR and PCT parameters, it readily meets the challenge of identifying, and discriminating between, fast-acting cytocidal drugs -and does so within 1 working day.
The development of this assay followed from the observation that the bioluminescent signal in parasites genetically modified to express a luciferase reporter protein is reduced in a concentrationand time-dependent way immediately following drug exposure when exposed to known cytocidal drugs. 16 This inherent dynamic response, a result of the short half-life of the luciferase, provides an apparent indirect report of the viability of the parasite. That is, dead and dying parasites do not synthesize new luciferase, the remainder being rapidly turned over. Here, using an adaptation of a lethality assay, 18 the concentration-dependent loss of bioluminescence over a 6 h drug bolus was shown to be related to that of the apparent lethal effect of a range of antimalarial drugs monitored following a drug wash and regrowth into a subsequent intraerythrocytic cycle of growth. 18 To facilitate a relative comparison of cytocidal activity between different antimalarial drugs, the bioluminescence protocol was adapted to use fold-IC 50 concentrations of drug bolus. Comparisons between the loss of bioluminescent signal at 6 h when exposed to between 0.33 Â IC 50 and 81 Â IC 50 concentrations correlated significantly with in vitro PCT at !3 Â IC 50 . Interestingly, the slopes for these correlations remained unchanged at concentrations >9 Â IC 50 , mimicking the observation of Sanz et al., 13 which suggests that a 10 Â IC 50 concentration is generally sufficient, irrespective of mode of action of a drug, to achieve its maximal rate of in vitro kill. Whilst the losses of bioluminescence signal at 6 h failed to consistently provide a significant correlation with in vitro PRR, the CVs are consistently >0.69% for concentrations of <3 Â IC 50 and more. Given these observations, the BRRoK assay was adapted to screen the MMV Malaria Box using concentrations between 0.33 Â IC 50 and 9 Â IC 50 . This choice balances the apparent saturation in in vitro cytocidal action at concentrations >9 Â IC 50 and the observation that concentrations as low as 0.33 Â IC 50 still elicited a measurable loss of bioluminescence from profoundly rapidly acting drugs such as dihydroartemisinin. A distinction between the BRRoK and in vitro PRR assays is the use of chloroquine-resistant and -susceptible strains, respectively. However, given the approach of using fold-IC 50 concentrations of drug, the effect on the interpretation of the relative rates of kill was considered minimal, and appears so from the correlation of benchmark drugs using both assays. The use of the fold-IC 50 concentration approach in the analysis of drug action in chloroquine-susceptible and -resistant strains is supported by the observation that the temporal accumulation of haemozoin shows no difference between these strains when the appropriate 1-or 2-fold IC 50 concentration of chloroquine is added. 32 Potential modes of action have been attributed to 135 compounds in the MMV Malaria Box, although for most the target association is considered tentative. 33 Using these data, compounds exhibiting three modes of action were correlated with the BRRoK assay data to explore the validity of the assay format ( Figure 6 ) -specifically, inhibition of: (i) the bc 1 complex of the mitochondrial electron transport chain; (ii) dihydroorotate dehydrogenase (DHODH), a key step in the de novo synthesis of pyrimidines in a parasite that otherwise lacks a pyrimidine salvage pathway; and (iii) PfATP4, a Na þ -ATPase located in the parasite's plasma membrane. These modes of action were selected as in vitro PRR data are available for drugs/compounds that share these modes of action, with at least 10 MMV compounds annotated for each. [33] [34] [35] [36] [37] [38] Fifteen compounds are annotated as inhibitors of the parasite's bc 1 complex and are all reported in the BRRoK assay as having a slow initial cytocidal action (PC1 between 25.2 and 100.9), comparable to the exemplar drug, atovaquone, sharing the same mode of action (PC1 ¼ 55.4, log PRR ¼ 2.9 and 99.9% PCT ¼ 90 h). 13 Twelve compounds are annotated as DHODH inhibitors, with five of these being structural analogues of the triazolopyrimidine early clinical trial candidate DSM265. 34 BRRoK data report these compounds as sharing a slow initial cytocidal action (PC1 between 23.1 and 68), with this apparent slow rate of kill correlating with the atovaquone-like in vitro PRR data available for DSM265 due to a lag phase of between 24 and 48 h before eliciting its cytocidal activity in vitro. 34 Of the 28 potential PfATP4 inhibitors in the MMV Malaria Box, 35 26 were screened here. In vitro PRR data are available for the exemplar PfATP4 inhibitors (þ)-SJ733, 36 a dihydroisoquinoline with a slow to moderate (between pyrimethamine and atovaquone) rate of kill, and KAE609/NITD609, 37 a spiroindolone with a moderate to fast (between pyrimethamine and artesunate) rate of kill. The majority of the potential PfATP4 inhibitors in the MMV Malaria Box were reported in the BRRoK assay (PC1 between À47.4 and À114.9) as having an initial rate of kill between the moderate mefloquine (PC1 ¼ À42.4, log PRR ¼ 3.7 and 99.9% PCT ¼ 43 h), comparable to the in vitro PRR reference pyrimethamine (log PRR ¼ 3.5 and 99.9% PCT ¼ 55 h) 13 and the fastacting dihydroartemisinin (PC1 ¼ À97.4). The fastest-acting PfATP4 inhibitor in the BRRoK assay was the spiroindolone MMV396749. The Malaria Box also contains five structural analogues of (þ)-SJ733. 35 Of these, four reported BRRoK data (between À16.4 and 49.1), falling between mefloquine and atovaquone, supporting the moderate to slow rate of kill of these dihydroisoquinolines. These data, taken together with the expected relative order of the benchmark antimalarial drugs tested, validates the application of the BRRoK assay in determining initial cytocidal activity across a diverse range of chemotypes.
Comparison of BRRoK with other available in vitro assays of rate of kill suggests a number of advantages to our approach. Two alternative assays offer an indirect measurement of cytocidal activity, either by monitoring mRNA levels or through the use of a modified [ essentially through the monitoring of erythrocyte reinvasion (reinvasion into fluorescently labelled erythrocytes) and growth postdrug challenge, i.e. the current gold standard offered through monitoring parasite recrudescence after limiting dilution. 13, 27 Apart from the recrudescence assay, these formats offer readouts of parasiticidal activity within 3-10 days, with the recrudescence assay taking between 21 and 28 days. The advantage of the recrudescence assay, however, is based on the fact that it provides a direct measurement of rate of kill, albeit in vitro conditions generate PRR values that are not always directly comparable to in vivo PRR measurements. 13, 28, 36, 39 The erythrocyte invasion viability assay, like the BRRoK assay, offers a relative measure of rate of kill, with classifications of slow (atovaquone-like), moderate (pyrimethamine-like) and fast (artemisinin-like). 27 Comparison of the PC1 values for the 30 MMV compounds and benchmark antimalarials similarly tested in the erythrocyte-invasion viability assay shows good correlation ( Figure S9) , with significant differences between PC1 values for drugs with fast and slow rates of kill as defined in the invasion assay. 27, 30 Compounds with a moderate rate of kill, however, showed no significant difference from compounds with a slow or fast rate of kill when compared with the BRRoK assay, but the sample size is small and there are outliers in both groups. These outliers may be potentially interesting as they likely represent differences between compounds being exposed for 6 h to trophozoites (BRRoK) and for between 24 and 48 h (invasion assay), encompassing most developmental stages of the intraerythrocytic asexual cycle, and may provide some guide to lag in cytocidal activity or stage-specific action.
The key limitation to the recrudescence assay is that it is only available as a low-throughput tool, due to the technical and timeconsuming challenge of the assay protocol -but it does provide the ability to discriminate between whether a compound meets the minimal essential or ideal TCP1 criteria for rate of kill. This discrimination between TCP1 candidates is similarly provided by the BRRoK assay, although here it is provided in 6 h from a microplate format assay requiring minimal manual intervention beyond a single-step lysis and readout protocol. The simplicity of this assay format offers a significant opportunity to scale up for highthroughput screening through semi-automation and denser microplate formats. Z 0 and S/B ratios comparable to those from the 96-well microplate assay can be achieved using 30 lL of intraerythrocytic culture (2% haematocrit and 2% parasitaemia), indicating that this robust assay can be readily adapted to a 384-or 1536-well microplate format. Whilst offering advantages in terms of speed, simplicity, scalability and discrimination, the BRRoK assay in its current format defines rate of kill only in terms of the relative immediate cytocidal action against trophozoite-stage parasites. This assay appears best placed in the early drug discovery pipeline, with priority hits from the BRRoK assay to be subsequently confirmed using the in vitro PRR assay.
The requirement for transgenic parasites expressing the luciferase reporter gene limits the genetic backgrounds available for this assay, and does represent a distinct limitation of this in vitro method when compared with the PRR and erythrocyte invasion assays. 13, 27 However, these transgenics can be reasonably readily generated using stable episomally maintained reporter plasmids, with the opportunity to extend the utility of the assay beyond the current limitation of trophozoite-stage parasites, to explore stage-specific rate of kill dynamics through the selection of gene-flanking sequences that would offer temporal expression at other intra-erythrocytic stages. The potential for a revised reporter construct in developing a cytocidal activity assay in ringstage parasites for the exploration of artemisinin action and resistance is a particularly relevant target of interest. One disadvantage evident from this study was that it took significantly longer to generate the IC 50 data for the MMV Malaria Box Ullah et al.
compounds than to perform the BRRoK assay. Typically, IC 50 data from large high-throughput screens are available for the 3D7 strain of P. falciparum, and were provided with the Malaria Box resource. Given that multiples of IC 50 are used in the BRRoK assay, and that the 9 Â IC 50 assay data best correlated with available in vitro PRR and PCT data, we examined whether Dd2-specific IC 50 data were actually needed to triage rapidly acting cytocidal compounds or whether a similar outcome could be achieved using the more widely available IC 50 data from the 3D7 strain. Using the available 3D7 data to provide a 9 Â IC 50 concentration against Dd2 luc , the loss of bioluminescence signal in a single-concentration/single-timepoint (6 h) triage assay was carried out with 396 of the MMV compounds and compared with the same data derived using our Dd2 IC 50 values (Figure 7a ). The loss of bioluminescence measured using the 3D7 IC 50 concentrations significantly correlate with those determined using the Dd2 IC 50 values (r 2 ¼ 0.88, P < 0.0001). Looking specifically at the 53 compounds that the BRRoK assay define as having an initial rate of kill at least as good as chloroquine, setting a threshold of discovery based on a 50% loss of bioluminescence signal using the 3D7 IC 50 concentration would ensure that >95% of these TCP1 candidates would be identified in this simplified assay format using the more readily available 3D7 data (Figure 7b ). The discovery rate using 3D7 IC 50 data falls as a more stringent bioluminescence signal threshold is applied, although the same is similarly true when using the actual Dd2 IC 50 data. This simple triage assay, utilizing the opportunities afforded through denser microplate formats and available 3D7 IC 50 data, provides the means for a quick and robust exploitation of the available chemical libraries in our search for rapid-acting cytocidal antimalarial drugs to meet the challenge of malaria control and eradication in a postartemisinin era. 14 (b) Plot representing the proportion of the 53 compounds from the full BRRoK assay that show an initial rate of cytocidal activity at least as good as that of chloroquine that would be identified when the indicated thresholds of bioluminescence signal post-treatment are chosen. The two curves represent the bioluminescence signal thresholds when 9 Â IC 50 concentrations of either the Dd2 or 3D7 strain is used in this assay. Note that selection of a 50% bioluminescence threshold, irrespective of the source of the IC 50 data used in the single-concentration/single-timepoint assay, identifies >95% of the MMV compounds shown in this report to have an initial cytocidal activity that would meet the minimal essential requirement for a TCP1 candidate. CQ, chloroquine.
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